Stifel maintains Buy rating on ORIC Pharmaceuticals, $18 price target

Stifel kept a Buy rating on ORIC Pharmaceuticals with a $18.00 price target, implying 36.7% upside from the Oct 23 close. The firm cited encouraging Phase 1b data for enozertinib and reduced risks for the MEVPRO-1 trial as reasons for the rating.

Original reporting
Published Oct 26, 2026, 4:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 4:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stifel maintains Buy rating on ORIC Pharmaceuticals, $18 price target — source image
Decision brief

The 30-second read

$ORICBullishMed
01

Why it matters

The data could trigger a short‑term rally and attract new long positions, especially given the $18 target versus current price.

02

Market read

The announcement offers a concrete catalyst for ORIC and may influence peer biotech valuations.

03

What to watch

Potential competition from other EGFR therapies and regulatory timelines could temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Stifel's note highlights new clinical data and a de‑risking of ORIC's pipeline, providing fresh analyst coverage.

Company-level read

Ticker impact

$ORICBullishHigh confidence
Context

Stifel upgraded ORIC with a Buy rating and $18 price target after releasing Phase 1b data showing 84% response rate in EGFR‑mutant NSCLC.

Expected impact

likely upward pressure as investors price in the strong response rate and de‑risking of the upcoming Phase 3 trial.

Evidence & confidence

Phase 1b data is material for biotech valuations; the upgrade and target raise provide a clear near‑term catalyst.

Market effects

Strengthens the broader EGFR‑mutant NSCLC therapeutic space and may lift peer biotech sentiment.

U.S. biotech sector could see modest gains on the back of the data.

Limited to biotech investors; no broad market effect.

Counterpoint

Some investors may remain cautious until Phase 3 data, viewing early‑stage results as preliminary.

Key entities

  • ORIC Pharmaceuticals

    Biotech firm developing EGFR‑mutant NSCLC therapies.

  • Stifel

    Equity research firm issuing the Buy rating.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo